Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03529942 · ClinicalTrials.gov registry record · Phase 3

Study to Evaluate the Effect of FX006 on Synovial Inflammation in Patients With OA of the Knee

A Phase 3 study of Osteoarthritis, Knee, sponsored by Pacira Pharmaceuticals.

Completed
Registry status
Phase 3
Development phase
129
Enrollment target
10
Study locations

NCT03529942: Completed Phase 3 study of Osteoarthritis, Knee, sponsored by Pacira Pharmaceuticals.

NCT03529942 is a Phase 3 study of Osteoarthritis, Knee that has completed, run by Pacira Pharmaceuticals. The registered enrollment target is 129 participants, below the 497-participant average among 112 other Osteoarthritis, Knee trials with a reported enrollment target (74% lower). The trial reports 10 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03529942, a Phase 3 study of Osteoarthritis, Knee, has completed, sponsored by Pacira Pharmaceuticals.

COMPLETED
Registry status
Phase 3
Development phase
129 participants
Enrollment target
10
Study locations

Study Summary

This is an open-label study assessing the effect of the administration of a single intra-articular (IA) injection of FX006 32 mg on synovial volume in patients with osteoarthritis (OA) of the knee.

Primary Outcome

Synovial volume (mm\^3) as measured by MRI and read by a central imaging vendor. Standardization was performed by dividing the model-derived least squares means and corresponding confidence intervals by the adjusted standard deviation (SD). Therefore, the mean standardized change represents the change in synovial volume expressed in standard deviation units.

Conditions Studied

Interventions

  • DRUG FX006 32 mg

Study Locations (10)

California

  • TriWest Research Associates, LLC - El Cajon
  • Biosolutions Research - La Mesa
  • Dream Team Clinical Research (formerly located in Anaheim) - Pomona
  • Dream Team Clinical Research - Pomona

Florida

  • Tampa Bay Medical Research, Inc. - Clearwater

Illinois

  • Rush University Medical Center - Chicago

North Carolina

  • Duke University Medical Center - Durham

Pennsylvania

  • Altoona Center for Clinical Research - Duncansville

Tennessee

  • PMG Research, Inc. d/b/a PMG Research of Knoxville - Knoxville

Other

  • University of Leeds - Leeds

Trial Details

FieldValue
Enrollment Target 129 participants
Start Date 2018-04-24
Est. Completion 2020-03-09
Phase Phase 3
Pacira Pharmaceuticals

88 total trials

What the finished NCT03529942 record still lists

NCT03529942 is an interventional study that assigns participants to a tested intervention. The registered 129 participants enrollment target is mid-sized for trials with a published cap, below the 497-participant average among 112 other Osteoarthritis, Knee trials with a reported enrollment target (74% lower).

The record links to 1 condition, with Osteoarthritis, Knee appearing as the primary indexed condition, and to 1 intervention - of which FX006 32 mg is the first listed.

NCT03529942 lists 10 locations in 7 states (California, Florida, Illinois).

Frequently Asked Questions

What is clinical trial NCT03529942 about?

NCT03529942 is a clinical study titled "Study to Evaluate the Effect of FX006 on Synovial Inflammation in Patients With OA of the Knee". This is an open-label study assessing the effect of the administration of a single intra-articular (IA) injection of FX006 32 mg on synovial volume in patients with osteoarthritis (OA) of the knee.

What is the current status of trial NCT03529942?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 129 participants. The study started on 2018-04-24. Estimated completion is 2020-03-09.

What conditions does trial NCT03529942 study?

This clinical trial studies the following conditions: Osteoarthritis, Knee.

What interventions are being tested in trial NCT03529942?

The interventions under investigation include: FX006 32 mg (DRUG).

Who is sponsoring clinical trial NCT03529942?

This trial is sponsored by Pacira Pharmaceuticals, which has 88 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03529942 being conducted?

This trial has 10 study locations across California, Florida, Illinois, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Osteoarthritis, Knee

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03529942's enrollment target sits among peer trials

129 53rd of 112 higher than 60 of 112 other Osteoarthritis, Knee trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Osteoarthritis, Knee trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03619850 · 129 participants · Phase 3

    A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)

  • NCT05704361 · 129 participants · Phase 1

    A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis

  • NCT05919849 · 129 participants · Phase 1

    Supporting Parents in Affirming Their Children's Experiences of Stigma

  • NCT06313749 · 129 participants · NA

    Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03529942, the US trial registry maintained by the National Library of Medicine. NCT03529942 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.